Printer Friendly

Adherex Technologies Announces Strengthened Intellectual Property Portfolio; New US Patent Expands Potential of Technology Application.

Business Editors & Health/Medical Writers

OTTAWA--(BUSINESS WIRE)--April 11, 2002

Adherex Technologies Inc. (TSE:AHX), a biotechnology company developing novel therapeutics based on cell adhesion technology, today announced it was issued a new US patent which allows the company to potentially broaden its platform technology.

The company's 13th US patent relates to nonclassical cadherins and will provide Adherex with protection for synthetic drugs designed to disrupt VE-cadherin. This cell adhesion protein is expressed by blood vessel cells but is different from the target of Exherin, Adherex's lead vascular targeting agent.

"The scientific community has recognized the importance of this type of compound, including in a peer-reviewed article appearing in the scientific journal, Blood (March 2001). We believe these compounds fit perfectly into our approach of effectively starving cancer tumors by attacking the blood vessels that feed them," said John Brooks, President & CEO of Adherex. "This intellectual property allows us to broaden our approach in targeting the cadherins that help hold the blood vessels together."

About Adherex Technologies

Adherex Technologies is an Ottawa-based biotechnology company that develops therapeutic drugs based upon its proprietary cell adhesion platform technology. The lead compound, Exherin, works to destroy the blood vessels that feed a cancerous tumor, essentially destroying the tumor's food supply. Adherex's unique cell adhesion platform has the potential for diverse applications, including drug delivery through the skin. For more information, please visit Adherex's Web site at

This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Certain information contained in this news release is forward-looking and is subject to unknown risks and uncertainties. The actual results, performance or achievements of the company may differ materially from the results, performance or achievements of the company expressed or implied by such forward looking statements.
COPYRIGHT 2002 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Apr 11, 2002
Previous Article:Kronos Continues Activity in Stock Repurchase Plan.
Next Article:Guidant Announces Live Webcast of its First Quarter Earnings Conference Call.

Related Articles
Adherex Technologies Reports Second Quarter Results-Company Encouraged by Results From Exherin Study.
Adherex Awarded Patent for Cancer Metastasis.
Adherex Technologies Reports Year-End Results for Fiscal 2002.
Adherex Issued New Patent Which Further Strengthens Anti-Cancer Portfolio - Intracellular Catenin Inhibition: A New Approach to Tumor Vascular...
Adherex Issued Cancer Diagnostics Patent: New Approach to Cancer Diagnostics and the Assessment of Cancer Progression.
Adherex Expands Patent Protection for Drug Delivery to Tumors.
Adherex to Reacquire Cadherin Biomedical Inc.
Adherex Technologies Issued Patent for Method of Improving Drug Delivery to Tumors.
Adherex Reports First Quarter 2005 Financial Results.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters